This company has been marked as potentially delisted and may not be actively trading. Ritter Pharmaceuticals (RTTR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock RTTR vs. MBX, RVNC, CKPT, AVTE, TSVT, SLRN, CYBN, BIOA, NLTX, and PROCShould you be buying Ritter Pharmaceuticals stock or one of its competitors? The main competitors of Ritter Pharmaceuticals include MBX Biosciences (MBX), Revance Therapeutics (RVNC), Checkpoint Therapeutics (CKPT), Aerovate Therapeutics (AVTE), 2seventy bio (TSVT), Acelyrin (SLRN), Cybin (CYBN), BioAge Labs (BIOA), Neoleukin Therapeutics (NLTX), and Procaps Group (PROC). Ritter Pharmaceuticals vs. Its Competitors MBX Biosciences Revance Therapeutics Checkpoint Therapeutics Aerovate Therapeutics 2seventy bio Acelyrin Cybin BioAge Labs Neoleukin Therapeutics Procaps Group MBX Biosciences (NYSE:MBX) and Ritter Pharmaceuticals (NASDAQ:RTTR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends. Does the media prefer MBX or RTTR? In the previous week, MBX Biosciences had 1 more articles in the media than Ritter Pharmaceuticals. MarketBeat recorded 1 mentions for MBX Biosciences and 0 mentions for Ritter Pharmaceuticals. MBX Biosciences' average media sentiment score of 0.95 beat Ritter Pharmaceuticals' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the media. Company Overall Sentiment MBX Biosciences Positive Ritter Pharmaceuticals Neutral Which has preferable valuation and earnings, MBX or RTTR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/AN/AN/AN/ARitter PharmaceuticalsN/AN/A-$10.13MN/AN/A Is MBX or RTTR more profitable? Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A N/A N/A Ritter Pharmaceuticals N/A N/A -162.05% Do insiders and institutionals believe in MBX or RTTR? 0.8% of Ritter Pharmaceuticals shares are owned by institutional investors. 52.2% of MBX Biosciences shares are owned by insiders. Comparatively, 15.4% of Ritter Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer MBX or RTTR? MBX Biosciences currently has a consensus target price of $37.50, indicating a potential upside of 200.60%. Given MBX Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe MBX Biosciences is more favorable than Ritter Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Ritter Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryMBX Biosciences beats Ritter Pharmaceuticals on 7 of the 8 factors compared between the two stocks. Get Ritter Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RTTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTTR vs. The Competition Export to ExcelMetricRitter PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$145.84M$790.73M$5.53B$9.05BDividend YieldN/A4.84%5.24%4.03%P/E Ratio-4.941.1327.5220.22Price / SalesN/A226.97421.02118.64Price / CashN/A23.4436.8958.07Price / Book31.606.298.045.67Net Income-$10.13M-$27.73M$3.18B$249.13M Ritter Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTTRRitter PharmaceuticalsN/A$3.16-3.2%N/A+1,700.6%$145.84MN/A-4.947MBXMBX Biosciences3.1218 of 5 stars$11.59+1.6%$37.50+223.5%N/A$388.89MN/A0.0036RVNCRevance Therapeutics2.7795 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500CKPTCheckpoint Therapeutics0.4915 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210AVTEAerovate TherapeuticsN/A$9.99+8.7%N/A-81.2%$289.56MN/A-3.3420High Trading VolumeTSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135CYBNCybin2.7503 of 5 stars$9.08+8.2%$86.00+847.7%N/A$208.90MN/A-2.0750News CoverageAnalyst RevisionHigh Trading VolumeBIOABioAge LabsN/A$4.24+2.7%N/AN/A$152.00MN/A0.00N/ANLTXNeoleukin TherapeuticsN/A$14.95-7.5%N/A-44.2%$140.50MN/A-4.8190High Trading VolumePROCProcaps GroupN/A$0.95-40.3%N/A-62.0%$107.18M$409.92M0.004,900Gap DownHigh Trading Volume Related Companies and Tools Related Companies MBX Biosciences Competitors Revance Therapeutics Competitors Checkpoint Therapeutics Competitors Aerovate Therapeutics Competitors 2seventy bio Competitors Acelyrin Competitors Cybin Competitors BioAge Labs Competitors Neoleukin Therapeutics Competitors Procaps Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTTR) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ritter Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RTTR Stock Alerts